Response Evaluation Criteria in Solid Tumors
"Response Evaluation Criteria in Solid Tumors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An internationally recognized set of published rules used for evaluation of cancer treatment that define when tumors found in cancer patients improve, worsen, or remain stable during treatment. These criteria are based specifically on the response of the tumor(s) to treatment, and not on the overall health status of the patient resulting from treatment.
| Descriptor ID |
D066066
|
| MeSH Number(s) |
E01.789.800.379 N04.761.559.590.800.569 N05.715.360.575.575.800.569
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Response Evaluation Criteria in Solid Tumors".
Below are MeSH descriptors whose meaning is more specific than "Response Evaluation Criteria in Solid Tumors".
This graph shows the total number of publications written about "Response Evaluation Criteria in Solid Tumors" by people in this website by year, and whether "Response Evaluation Criteria in Solid Tumors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 0 | 3 | 3 |
| 2016 | 0 | 6 | 6 |
| 2017 | 0 | 9 | 9 |
| 2018 | 2 | 10 | 12 |
| 2019 | 2 | 9 | 11 |
| 2020 | 1 | 14 | 15 |
| 2021 | 1 | 7 | 8 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 3 | 3 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Response Evaluation Criteria in Solid Tumors" by people in Profiles.
-
Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor. J Clin Oncol. 2024 Apr 10; 42(11):1301-1310.
-
BETA prime: a first-in-man phase 1 study of AdAPT-001, an armed oncolytic adenovirus for solid tumors. Cancer Gene Ther. 2024 Apr; 31(4):517-526.
-
Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST). Ann Oncol. 2024 Mar; 35(3):267-275.
-
Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers. Hepatology. 2023 09 01; 78(3):758-770.
-
Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study. Eur J Cancer. 2022 Sep; 172:340-348.
-
Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study. Lancet Oncol. 2021 09; 22(9):1312-1321.
-
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2021 09; 22(9):1290-1300.
-
Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial. Gynecol Oncol. 2021 08; 162(2):375-381.
-
Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers. J Immunother Cancer. 2021 04; 9(4).
-
The efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma. Cancer Med. 2021 04; 10(7):2293-2299.